


ACTIV-2d, a global phase 3 trial of novel investigational COVID-19 oral antiviral agent, launches

August 22 2022



Credit: Pixabay/CC0 Public Domain

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded its focus to conduct research into COVID-19, today announced the initiation of ACTIV-2d, a global,



phase 3, multicenter trial to evaluate the impact of S-217622, an investigational oral COVID-19 antiviral agent. ACTIV-2d will evaluate the safety and efficacy of S-217622 as a once-daily treatment to reduce the duration of COVID-19 symptoms in non-hospitalized adults with early COVID-19.

S-217622, a selective inhibitor of the 3CL protease (an enzyme essential for the replication of SARS-CoV-2) was created through joint research between Hokkaido University and Shionogi & Co. Ltd. Recent results from a trial conducted in Japan and Korea demonstrated that patients treated with S-217622 showed a significant and rapid decrease in viral level and culturability after the third dose of S-217622 compared to placebo. Previous clinical trials also showed that S-217622 was well-tolerated, with few treatment-related discontinuations, and no serious adverse events or death. The most common adverse events were mild headache and transient reduction in HDL cholesterol. Additionally, S-217622 has recently demonstrated high in vitro antiviral activity against the Omicron subvariants (BA.4 and BA.5), with antiviral potency against other existing variants.

ACTIV-2d is a global phase 3, multicenter, randomized, double-blind, 24-week study evaluating whether S-217622 can reduce the time it takes for COVID-19 symptoms to resolve among participants who have tested positive for SARS-CoV-2 in the outpatient setting and started experiencing symptoms within five days of enrolling. The study will include people at lower and higher risk of progression to severe COVID-19.

"S-217622 has the potential to simplify COVID-19 treatment, as it is administered once a day without a boosting agent," said Annie Luetkemeyer, M.D., University of California, San Francisco and a lead investigator of S-217622. "As COVID-19 remains a major global concern, we need to increase our treatment options. We are hopeful that



S-217622 will be an important addition to the COVID-19 treatment tool kit."

ACTIV-2d is being conducted with trial sites in countries in Europe, South America, North America, Africa, and Asia. Approximately 1,490 participants will be randomized in a 1:1 ratio receiving either S-217622 or placebo. Participants may take locally provided COVID-19 treatment after enrollment, as long as it is compatible with S-217622.

ACTIV-2d is led by Kara W. Chew, M.D., M.S., University of California, Los Angeles (UCLA), Dr. Luetkemeyer, and Davey Smith, M.D., University of California, San Diego (protocol co-chairs) and David Alain Wohl, M.D., University of North Carolina (UNC) and Eric S. Daar, M.D., Lundquist Institute at Harbor-UCLA Medical Center (vice-chairs), and is supported by Judith Currier, M.D., M.Sc., UCLA (ACTG Chair) and Joseph J. Eron, M.D., UNC, (ACTG Co-Chair).

Provided by AIDS Clinical Trials Group

Citation: ACTIV-2d, a global phase 3 trial of novel investigational COVID-19 oral antiviral agent, launches (2022, August 22) retrieved 14 January 2023 from <u>https://medicalxpress.com/news/2022-08-activ-2d-global-phase-trial-covid-.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.